淋巴瘤相关噬血细胞综合征治疗研究进展

Progress in treatment of lymphoma-associated hemophagocytic syndrome

淋巴瘤相关噬血细胞综合征(LAHS)在继发性噬血细胞综合征(HPS)中占有较大比例,而且预后差。LAHS分为化疗期合并的HPS和淋巴瘤诱导的HPS两类,化疗期合并的HPS的治疗以控制感染为关键。淋巴瘤诱导的HPS的治疗较为复杂,除了传统方法,目前已有新的策略;及时恰当的治疗可以使患者近期及远期预后得到明显改善。文章对LAHS的治疗研究进展进行总结。

Lymphoma-associated hemophagocytic syndrome(LAHS)accounts for a large proportion of secondary hemophagocytic syndrome(HPS)and has a poor prognosis.LAHS can be divided into two categories:HPS combined with chemotherapy and lymphoma-induced HPS.The key to the treatment of HPS combined with chemotherapy is to control the infection.While the treatment of lymphoma-induced HPS is complicated,there are new strategies in addition to traditional methods.Timely and appropriate treatment can significantly improve the short-term and long-term prognosis of patients.This article summarizes the progress in treatment of LAHS.